Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi) in Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primary Biliary Cirrhosis
Conditions
Interventions
LUM001
Placebo
+1 more
Locations
24
United States
Scripps Clinic
La Jolla, California, United States
University of California at Davis
Sacramento, California, United States
University of Miami
Miami, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
University of Louisville
Louisville, Kentucky, United States
Start Date
August 1, 2013
Primary Completion Date
April 1, 2015
Completion Date
April 1, 2015
Last Updated
March 27, 2019
NCT07304843
NCT07449793
NCT06755541
NCT07296458
NCT07161245
NCT06861465
Lead Sponsor
Mirum Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions